Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia

2000 ◽  
Vol 79 (10) ◽  
pp. 533-542 ◽  
Author(s):  
M. Flasshove ◽  
P. Meusers ◽  
J. Schütte ◽  
R. Noppeney ◽  
D. W. Beelen ◽  
...  
Leukemia ◽  
2006 ◽  
Vol 20 (3) ◽  
pp. 404-409 ◽  
Author(s):  
G Heil ◽  
◽  
D Hoelzer ◽  
M A Sanz ◽  
K Lechner ◽  
...  

2020 ◽  
pp. 1-2
Author(s):  
Yi-Qian ZHU ◽  
CHEN Bao-An ◽  
Cheng Jian ◽  
Yi-Qian ZHU

Acute myeloid leukemia (AML) is a common malignancy of the blood system, and most patients are so ill that they often die if they are untreated in time. In recent years, with the improvement of chemotherapy drugs and methods, the complete remission rate has been significantly improved, but the long-term survival rate still has great room for improvement. This review summarized the influencing factors related to the long-term survival of AML patients through reading and sorting out multiple pieces of literature.


2009 ◽  
Vol 15 (5) ◽  
pp. 1762-1769 ◽  
Author(s):  
Yanping Guo ◽  
Kathleen Köck ◽  
Christoph A. Ritter ◽  
Zhe-Sheng Chen ◽  
Markus Grube ◽  
...  

2020 ◽  
Vol 26 (2) ◽  
pp. 292-295 ◽  
Author(s):  
Satoshi Ichikawa ◽  
Noriko Fukuhara ◽  
Shotaro Watanabe ◽  
Yoko Okitsu ◽  
Koichi Onodera ◽  
...  

Cancer ◽  
1997 ◽  
Vol 80 (S11) ◽  
pp. 2199-2204 ◽  
Author(s):  
Frederick R. Appelbaum ◽  
Kenneth J. Kopecky

Sign in / Sign up

Export Citation Format

Share Document